Search PubMed⌕ Search

Biomedical subjects

P Gaudreau

Publications and source records attributed to P Gaudreau.

At least 73 records · Page 4Linked to original sources
PubMed1990

Effect of a potent analog of human growth hormone-releasing factor on carcass composition and quality of crossbred market pigs.

The effect of a human growth hormone-releasing factor (hGRF) analog ([desamino-Tyr1, D-Ala2, Ala15] hGRF(1-29)NH2) on the carcass composition of crossbred barrows was evaluated. pH, color and collagen content were measured on 74 animals distributed among the following five treatments started at about 50 kg BW: T1, control saline three times daily (TID); T2, hGRF analog (1.66 micrograms/kg, TID); T3, hGRF analog (3.33 micrograms/kg, TID); T4, hGRF analog (6.66 micrograms/kg, TID) and T5, hGRF analog (10 micrograms/kg, once daily). Animals were slaughtered at approximately 106 kg BW giving an average of 55 d on test. Carcass composition was determined on eight animals from T1 and eight animals from T4. The left side of each carcass was divided into four untrimmed commercial cuts: ham, loin, shoulder and belly, which then were dissected into muscle, separable fat, bone and skin. Ham, loin and belly weights were not affected by GRF treatment, but shoulder weight was increased (P less than .05; 10.11 vs 11.15 kg, SE = .21). There was an increase (P less than .0.05) in muscle content of all the cuts considered and a concomitant decrease (P less than .05) in fat content. The analog increased muscle weight by 16% and decreased fat weight by 25% in the pooled tissues of the shoulder, ham and loin. Overall, hGRF analog increased skin and bone weights by 39% and 19%, respectively. Chemical analysis demonstrated that the hGRF analog increased overall protein accretion in the carcass by 10.5% and decreased crude fat by 28.7%.(ABSTRACT TRUNCATED AT 250 WORDS)

Adipose Tissue↗
PubMed1990

Effect of human growth hormone-releasing factor and(or) thyrotropin-releasing factor on hormone concentrations in dairy calves.

To determine the effect of chronic treatment with human growth hormone-releasing factor (1-29)NH2 (GRF) and(or) thyrotropin-releasing factor (TRF), 20 calves averaging 70.2 kg BW were divided into four groups (n = 5) according to a 2 X 2 factorial design. For 86 d, calves in each group received twice daily s.c. injections of either .9% NaCl, GRF (5 micrograms/kg BW), TRF (1 microgram/kg BW) or GRF (5 micrograms/kg BW) plus TRF (1 microgram/kg BW). On d 87, all calves received a s.c. injection of GRF (5 micrograms/kg BW) plus TRF (1 microgram/kg BW). Blood samples were collected every 20 min for 18 h on d 1, 29, 57 and 85, and for 8 h on d 87. Hormone responses were measured as area under the hormone concentration curve over time. GRF and TRF acted in synergy (P less than .10) on GH release throughout the treatment period. Growth hormone responsiveness to GRF and(or) TRF decreased (P less than .01) with days of treatment, but this decrease was due to aging rather than to chronic treatment, because GH response to GRF plus TRF was similar (P greater than .10) between control and treated calves on d 87. TRF increased prolactin (Prl) concentration until the end of the treatment period (P less than .01). The response of thyroid-stimulating hormone (TSH) to TRF disappeared (P greater than .10) after 1 mo of treatment, whereas the thyroxine (T4) response decreased (P less than .01) throughout the treatment period. GRF did not induce nor did it interact with TRF on TSH and T4 release.(ABSTRACT TRUNCATED AT 250 WORDS)

Animals↗
PubMed1990

Effects of long-term haloperidol treatment on the responsiveness of accumbens neurons to cholecystokinin and dopamine: electrophysiological and radioligand binding studies in the rat.

Cholecystokinin (CCK) and dopamine (DA) coexist in a subpopulation of neurons of the ventral tegmental area projecting to the nucleus accumbens. The present experiments were undertaken to determine the effect of acute and long-term administration of haloperidol on the responsiveness of accumbens neurons to microiontophoretic applications of the sulfated cholecystokinin octapeptide (CCK-8S), kainate (KA), and DA and on the density of CCK, D1, and D2 receptors determined by radioautography. Acute administration of haloperidol (1 mg/kg, i.v.) did not modify the neuronal responsiveness to DA and KA but increased that to CCK-8S. Long-term treatment with haloperidol decanoate (4 mg/kg/week, i.m., for 3-5 weeks) induced a marked increase in the responsiveness to CCK-8S, without noticeable change of that to DA and KA. After a 5 week treatment, significant increases in the amounts of CCK and D2 binding were found in the nucleus accumbens, whereas D1 binding parameters remained unchanged. Since long-term haloperidol treatment results in a depolarization inactivation of A10 dopaminergic neurons, these results suggest that, despite the reduced firing activity of mesolimbic dopaminergic neurons induced by the long-term haloperidol treatment, dopamine is still released in an amount sufficient to maintain a normal neuronal responsiveness of postsynaptic accumbens neurons to DA, whereas the release of CCK is possibly decreased to a greater extent, resulting in an enhanced responsiveness of the neurons to this peptide.

Animals↗
PubMed1989

Castration and testosterone effects on endogenous and somatocrinin-induced growth hormone release in intact and castrated male pigs.

Growth hormone (GH) release is influenced mainly by two hypothalamic factors, growth hormone-releasing factor (GRF) and somatostatin and is modulated by other hormones such as gonadal steroids. The objective of this study was to determine if castration (CA) and exogenous testosterone (TE) affect endogenous and GRF-induced GH release. Purebred Yorkshire male pigs (n = 32) were assigned to one of the following treatments: T1:CA; T2:CA +/- TE; T3: intact (IN); T4: IN +/- TE, in a 2 x 2 factorial design. Piglets were castrated at 3 days of age. Testosterone propionate (1.0 mg/kg) in sesame oil (2 ml) or sesame oil alone was injected sc SID during a 10-day period before each sampling day at 9, 15 and 21 weeks of age. Jugular blood samples were collected for a 6-hr period preceding and following iv injection of hGRF (1-29)NH2 (10 micrograms/kg). These procedures were repeated at 9, 15 and 21 weeks of age. The overall mean GH levels and the area under the GH peaks before and after GRF stimulation were lower (P less than .05) in castrated animals than in intact animals. Testosterone treatment increased (P less than .05) circulating TE levels and increased the amplitude of the endogenous GH peaks but did not affect (P greater than .05) the GRF-induced GH release. Increasing age produced a marked reduction of the amplitude of the GH peaks, the area under the GH peaks, the baseline mean and the overall mean GH levels during the 6-hr period preceding GRF injection. The present data support the hypothesis that castration in pigs reduces circulating and GRF-induced GH release. Exogenous testosterone for 10 days did not stimulate endogenous or GRF-induced GH release with the exception of the amplitude of the endogenous GH peaks.

Animals↗
PubMed1989

In vitro and in vivo growth hormone responsiveness to growth hormone-releasing factor in male and female Zucker rats.

In order to determine whether there is an anomaly in the pituitary responsiveness to growth hormone (GH)-releasing factor in the genetically obese rat, we examined the in vitro and in vivo effects of rGRF(1-29)NH2 (GRF) on GH release in male and female Zucker rats. The effect of increasing GRF concentrations (1.56, 6.25, 12.5 25 and 50 pM) was first tested on GH release from freshly perifused anterior pituitary cells. In both sexes, the GH response per one pituitary equivalent to each GRF concentration tested was reduced in the obese group. However, when GH release was expressed as a percent of initial cell GH content, there was no difference between the lean and the obese groups. Furthermore, under pentobarbital anesthesia, GRF was injected intravenously at two consecutive doses of 0.8 and 4.0 microgram/kg body weight in obese and lean animals. In both sexes, the GH response to each dose of GRF tested was decreased in the obese group. Basal serum GH concentrations were similar in male and female obese rats compared to their respective lean siblings. In conclusion, this study demonstrates a decrease of the in vitro and in vivo pituitary response to GRF in the obese Zucker rat, suggesting a possible secondary defect at the pituitary level.

Animals↗
PubMed1989

Effects of active immunization against somatostatin on serum growth hormone concentration in growing pigs: influence of fasting and repetitive somatocrinin injections.

Three experiments were conducted with growing pigs actively immunized against a protein-conjugated somatostatin (SRIF) in Freund's adjuvant. In the first experiment, blood from 24-week-old pigs (seven immunized and eight control) was sampled at 20-min intervals for 6 h to evaluate basal GH concentrations. The animals were then injected iv with porcine GH-releasing factor (GRF)-(1-29)NH2 (10 micrograms/kg). Before GRF stimulation, immunized animals had higher (P less than 0.05) baseline mean GH levels (2.6 vs. 1.4 ng/ml) and area under the GH curve (AUC; 1632 vs. 779 ng/min.ml); they also had higher AUC after GRF administration (4268 vs. 1972 ng/min.ml). In a second experiment eight immunized and eight control pigs were injected iv four times at 90-min intervals with porcine GRF (10 micrograms/kg). Control pigs responding to the first injection did not respond to the second and third, and those responding to the second did not respond to the first, third, and fourth, indicating a decreased responsiveness that was longer than 3 h post-GRF response in control pigs. SRIF-immunized pigs had a more consistent GH response to the GRF injections. Overall, a reduced response was observed after the second and the fourth injections in immunized pigs, although five and six of eight animals had a GH peak response higher than 10 ng/ml during these periods. In a third experiment, effects of fasting, GRF, and SRIF immunization were studied. Immunization and fasting had their own positive effects on serum GH levels. Immunization increased baseline mean GH levels (5.0 vs. 2.2 ng/ml) and total AUC before (2318 vs. 1073 ng/min.ml) and after (1886 vs. 910 ng/min.ml) iv GRF stimulation (10 micrograms/kg) compared to controls. Fasting increased the mean baseline GH level (4.5 vs. 2.6 ng/ml), and it increased AUC before exogenous GRF stimulation (2009 vs. 1392 ng/min.ml). In conclusion, SRIF in pigs seems to be a potent GH-governing factor, since, when inhibited, baseline mean GH levels increase, and a consistent response to GRF is observed. Fasting could increase GH concentrations by different ways: decreasing SRIF release and increasing GRF release or modifying the sensitivity of the somatotrophs to both factors.

Animals↗
PubMed1989

Effect of human somatotropin-releasing factor and photoperiods on carcass parameters and mammary gland development of dairy heifers.

Forty-eight heifers (3 mo old) were subjected for 35 wk to twice daily s.c. injections of saline or human somatotropin-releasing factor (5 microgram.kg-1 BW) and photoperiod of 8 h (short day) or 16 h (long day) of light daily according to a 2 X 2 factorial design. There was no treatment effect on slaughter weight, withers height, and carcass length. Somatotropin-releasing factor increased thymus weight, metacarpal length, and protein content of the carcass but decreased carcass fat content. Long day photoperiod increased chest girth, pituitary weight, and carcass yield. Effects of somatotropin-releasing factor and photoperiod were not additive on volume of mammary parenchymal tissue; there was also a treatment interaction on liver and lung weights. However, extraparenchymal mammary tissue was decreased by human somatotropin-releasing factor and short day photoperiod. In conclusion, use of somatotropin-releasing factor and photoperiod treatments affected carcass parameters and composition and mammary growth.

Animals↗
PubMed1988

Mechanism of inhibition of herpes simplex virus (HSV) ribonucleotide reductase by a nonapeptide corresponding to the carboxyl terminus of its subunit 2. Specific binding of a photoaffinity analog, [4'- azido-Phe6] HSV H2-6(6-15), to subunit 1.

Herpes simplex virus (HSV) ribonucleotide reductase activity is specifically inhibited by a synthetic peptide, Tyr-Ala-Gly-Ala-Val-Val-Asn-Asp-Leu (HSV H2-(7-15], corresponding to the carboxyl terminus of its subunit 2 (H2). In order to elucidate the mechanism of action of the nonapeptide a photoreactive analog, [4'-azido-Phe6]HSV H2-(6-15), was synthesized. The photoaffinity probe inhibits HSV ribonucleotide reductase activity, and when radioiodinated, it specifically labeled three viral proteins of 144, 95, and 85 kDa. We demonstrated by immunoprecipitation of the 144- and 95-kDa photolabeled proteins with antibodies specific to subunit 1 (H1) of HSV ribonucleotide reductase that the nonapeptide interacts with H1 and probably with its degradation products. Moreover, we obtained evidence that this specific binding is directly responsible for the ribonucleotide reductase inhibition.

Affinity Labels↗
PubMed1988

Long-term maintenance of growth hormone secretion in perifused rat anterior pituitary cells.

We studied the effect of rat growth hormone-releasing factor-(1-43) acid, rGRF(1-43)OH, on the long-term secretion of rat growth hormone (rGH) in dispersed primary cultured cells of rat anterior pituitaries over a period of 7 days or longer. Results of the perifusion assay show that freshly dispersed cells secrete more rGH than 4-day-old redispersed cells (P less than 0.05), that a stabilization period ranging from 4 to 24 h allows a greater production of rGH per day than longer periods (P less than 0.05) and that the working concentrations of rGRF-(1-43)OH and prostaglandin E2 (PGE2) that insured the best responsiveness and longer viability are 50 pM and 10-1000 nM, respectively. Under these conditions, the cells continued secreting rGH after 42 days of perifusion, and 315 milligrams of rGH was produced over that period.

Animals↗
PubMed1988

Serum growth hormone release during a 60-hour period in growing pigs.

Growth hormone (GH) profiles were measured during a 60-hour period in four castrated male and five female, 20-week-old Yorkshire pigs. During this period, GH release was not affected by feeding when measured at 2, 4 and 8 hr before and after feeding time. A photoperiod of 12 hr light and 12 hr darkness produced a decrease (P less than .05) in baseline mean GH levels from 4.0 to 3.5 ng/ml during periods of darkness. This effect was observed in both genders. Females and castrated males exhibited (P greater than .05) similar baseline GH levels and identical numbers of GH peaks during feeding and photoperiod studies. However, during these periods, the amplitude of the GH peaks and areas under the GH curves were greater (P less than .05) in females. These results indicate that: 1) feeding did not influence GH secretion; 2) darkness produced a decrease in the baseline GH levels in both sexes; and 3) females secreted more GH than castrated males of the same age.

Animals↗
PubMed1988

Effect of human growth hormone-releasing factor (1-29)NH2 on growth hormone release and milk production in dairy cows.

Twelve cows (209 d in lactation, 642 kg BW) were used in an experiment conducted over four 10-d periods (one preinjection, one injection, and two postinjection). Gelatine (n = 6) or 10 mg of growth hormone-releasing factor in gelatine (n = 6) was injected subcutaneously at 1000 h every day on d 11 to 20. Data were averaged for the last 5 d of each period. During the injection period, milk, fat, and protein yields increased by 3 kg.d-1 (14.3%), .14 kg.d-1 (16.7%), and .12 kg.d-1 (15.4%), respectively. Moreover, milk, fat, and protein yields for the treated cows remained higher than for the control cows until the last postinjection period. Growth hormone response was evaluated from blood samples withdrawn from 2 h prior to 8 h postinjection on d 11, 15, and 20 and on d 40. After growth hormone-releasing factor injection, peaks and area under the curve were 24.5, 30.8, and 47.0 ng.ml-1 and 2475, 3979, and 3741 ng.ml-1.min-1 on d 11, 15, and 20, respectively. On d 40, there was no difference in growth hormone concentrations in blood between control and treated cows. These results demonstrate that 10 d of daily injection of a growth hormone-releasing factor increases milk production by 14.3% (3 kg.d-1) and still induces growth hormone release at the end of the injection period without any sign of refractoriness.

Animals↗
PubMed1988

Serum growth hormone release in response to a growth hormone-releasing factor analog during and after anesthesia in pigs.

The objective of this study was to evaluate the time course for full recovery of the growth hormone governing system and somatocrinin response after anesthesia. Sixteen Yorkshire gilts aged 32 weeks were divided into three groups: saline (n = 6), anesthesia + saline (n = 5) and anesthesia + somatocrinin (n = 5). Under anesthesia, the area under the growth hormone curve was increased (P less than 0.05) from 1172 +/- 184 to 2807 +/- 1002 ng.min.mL-1, and a more consistent growth hormone response to somatocrinin was observed; all animals responded immediately, while only three out of five did so four hours before anesthesia. Sixteen and 40 hours after anesthesia, basal and stimulated growth hormone levels were comparable to those of unanesthetized controls, suggesting a prompt recovery from the effects of anesthesia. These data indicate that anesthetized pigs release higher quantities of growth hormone and have a more consistent growth hormone response to somatocrinin. A full recovery of basal and somatocrinin-induced growth hormone release was observed as soon as 16 hours after anesthesia.

Anesthesia↗
PubMed1987

Structure-activity studies on synthetic peptides inhibiting herpes simplex virus ribonucleotide reductase.

Herpes simplex virus type 1 and type 2 (HSV-1 and HSV-2) ribonucleotide reductase is formed by the association of two nonidentical subunits. A peptide corresponding to the COOH terminus of the subunit 2, Tyr-Ala-Gly-Ala-Val-Val-Asn-Asp-Leu (H2-(7-15)), has been shown to completely inhibit the reductase activity (IC50 = 36 microM) without affecting the host isoenzyme. In order to study the relationship between chemical requirements and inhibitory potencies, a series of peptides, including fragments and analogs of H2-(7-15), were synthesized. The minimum active core can be assigned to the Val-Val-Asn-Asp-Leu sequence (IC50 = 760 microM). N alpha-Extended peptides, such as Ser-Thr-Ser-Tyr-Ala-Gly-Ala-Val-Val-Asn-Asp-Leu (H2-(4-15)) and Glu-Cys-Arg-Ser-Thr-Ser-Tyr-Ala-Gly-Ala-Val-Val-Asn-Asp-Leu (H2-(1-15) ), respectively, have inhibitory potencies 2.1- and 1.4-fold greater than the nonapeptide H2-(7-15). N alpha-Deamination or acetylation of H2-(7-15) increases its potency by 1.8- and 3.0-fold, respectively, whereas amidation of the alpha-carboxylic function diminishes its activity by 3.2-fold. These results indicate that the alpha-amino group is not essential for maximum potency but suggest that a free carboxylic function is required. Substitution of Tyr7 or Ala8 by their respective D-isomer leads to a decrease of potency, suggesting that a specific conformation of the NH2-terminal portion is required to have a maximum activity. Monosubstitution in positions 11, 13, 14, and 15, by L-alanine completely abolishes activity stressing the importance of each amino acid residue contained in the minimum active core. Finally, nonapeptides corresponding to the COOH-terminal portion of the subunit 2 of Epstein-Barr and varicella-zoster virus ribonucleotide reductases also inhibit the HSV-1 reductase activity. The varicella-zoster virus nonapeptide is 4.0 times more potent than H2-(7-15), whereas the Epstein-Barr virus nonapeptide is 3.1 times less potent. These results should help us to design a new generation of potent inhibitors of herpes virus ribonucleotide reductases.

Amino Acid Sequence↗
PubMed1987

Structure-activity studies of C- and N-terminal fragments of cholecystokinin 26-33 in guinea pig isolated tissues.

In vitro structure-activity studies with cholecystokinin (CCK)/gastrin-related peptides, including C- and N-terminal fragments of CCK 26-33, were undertaken in guinea pig gallbladder and ileum. The general order of potency in both smooth muscle preparations is CCK 26-33 greater than CCK 1-33 greater than 27-33 much much greater than nonsulfated (NS) CCK 26-33 greater than pentagastrin greater than CCK 30-33. None of the CCK fragments exhibit antagonistic properties such as in guinea pig, rat and mouse pancreatic acinar cells and hog duodenum. These observations suggest the existence of CCK receptor sub-types in peripheral tissues.

Animals↗
PubMed1987

Synergism and diurnal variations of human growth hormone-releasing factor (1-29)NH2 and thyrotropin-releasing factor on growth hormone release in dairy calves.

Sixteen male Holstein calves averaging 168 kg body weight (BW) were used to determine the effects of human growth hormone-releasing factor (1-29)NH2 (hGRF (1-29)NH2; .22 micrograms/kg BW), thyrotropin-releasing factor (TRF; .165 micrograms/kg BW) or hGRF (1-29)NH2 plus TRF (.22 and .165 micrograms/kg BW, respectively) on growth hormone (GH) release in animals exposed to 16 hr of light (L): 8 hr of dark (D) (lights on at 0100 hr) and hGRF plus TRF (.22 and .165 micrograms/kg BW, respectively) in animals exposed to 8L:16D (lights on at 0900 hr). For each treatment, times of iv injection were 0400, 1000, 1600 and 2200 hr. In animals exposed to 16L:8D, average GH peaks reached after hGRF (1-29)NH2 or TRF injections were 49.7 and 32.0 ng/ml while the area under the GH response curve (AUC) were 1247 and 1019 ng/ml.min, respectively. There was no significant effect of times of injection on GH release following the separate injection of hGRF(1-29)NH2 or TRF. In animals exposed to 16L:8D, GH peaks and AUC after hGRF plus TRF injections were 226.4, 189.2 and 116.8 ng/ml, and 4340, 3660 and 2415 ng/ml.min at 0400, 1000 and 1600 hr (lights on), respectively but only 42.3 ng/ml and 1692 ng/ml.min at 2200 hr (lights off). In animals exposed to 8L:16D, GH levels and AUC after hGRF plus TRF injections reached 177.5 and 180.5 ng/ml, and 2759 and 3704 ng/ml.min at 1000 and 1600 hr (lights on) but only 84.0 and 72.7 ng/ml, and 1544 and 1501 ng/ml.min at 0400 and 2200 hr (lights off), respectively.(ABSTRACT TRUNCATED AT 250 WORDS)

Animals↗
PubMed1987

Influence of age and sex on basal secretion of growth hormone (GH) and on GH-induced release by porcine GH-releasing factor pGRF(1-29NH2) in growing pigs.

The aim of this study was to determine the effect of age and sex on basal secretory patterns of growth hormone (GH) and growth hormone-releasing factor (GRF) induced GH release. Eighteen pigs (9 castrated males and 9 females) were stimulated with pGRF(1-29)NH2 at 7,11,15,19 and 23 weeks of age. Blood samples were taken from each animal via jugular vein cannulae every 20 min, from 6 hr before to 5 hr after iv GRF administration at a dose of 4 micrograms/kg. GH baseline levels, amplitude of the GH peaks, area under the GH peaks and the overall mean of GH serum levels decreased (P less than .001) with age in both sexes. Age also had a marked effect on GRF-induced GH release: the amplitude of GH peaks and area under the GH peaks decreased (P less than .001) with age. The GH response to pGRF(1-29)NH2 varied considerably, depending on the timing of the episodic endogenous secretion of GH. An immediate response (less than 30 min) was observed when GRF was injected at the end of a trough period or at the beginning of a peak, but there was no immediate response when GRF was injected at the end of a peak or at the beginning of a trough period. Our results show that both endogenous GH secretion and pGRF(1-29)NH2-induced GH release declines with age, suggesting a decreased sensitivity of the somatotroph cells to GRF with age; and that the high variability of the GH response to pGRF(1-29)NH2 stimulation depends greatly on the timing of the episodic endogenous GH release, thus implying a possible episodic endogenous somatostatin secretion by the hypothalamus.

Age Factors↗